APSR2026-700

 
Late-Breaking
Submitted
Oral Presentation
AO28-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1212842-46903-ASPIRE Study APSR 2026_433832.pptx
Format: PPTX Only
 
Format: PDF Only
09. Asthma
12

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Reinalyn Luceño - University of Perpetual Help Medical Center Department of Internal Medicine Las Piñas Philippines
Anjuli May Jaen - Iloilo Doctors' Hospital Department of Internal Medicine Iloilo Philippines
Marie Grace Dawn Isidro - West Visayas State University Medical Center Department of Internal Medicine Iloilo Philippines
Adelito Posas - Posas Medical Clinic Posas Medical Clinic Puerto Princesa Philippines
Sheng-Hao Lin * Changhua Christian Hospital Department of Internal Medicine Changhua Taiwan
Ching-Hsiung Lin - Changhua Christian Hospital Department of Internal Medicine Changhua Taiwan
Kanok Pipatvech - Nan Hospital Nan Hospital Nan Thailand
Gerald Ivan Estrelon - AstraZeneca Pharmaceuticals Philippines Inc., Medical Affairs Taguig City Philippines
Natcha Jarumpornsakul - AstraZeneca Thailand Ltd Medical Affairs Bangkok Thailand
Jia-Ling Shih - AstraZeneca Taiwan Ltd Site Management and Monitoring Department Taipei Taiwan
Hsien-Tsai Chiu - AstraZeneca Taiwan Ltd Medical Department Taipei Taiwan
Clara Hon-Ying Tsai - AstraZeneca Taiwan Ltd Medical Department Taipei Taiwan
 
 
 
Presenting Author Details
SHENGHAO
LIN
cmdr.linsh@gmail.com
+886910653519
31-40
Taiwan
Original Research
Impact of a SABA-Challenged Environment Program on Prescription Patterns and Healthcare Resource Utilization in Asian Asthma Patients: The ASPIRE Study
Maximum 25 words
Abstract Content
Short-acting beta-2 agonist (SABA) overuse (≥3 canisters/year) is associated with increased asthma exacerbations and healthcare burden worldwide. In Asia, suboptimal use of controller treatment, reliance on SABA and challenges of patients' access to anti-inflammatory reliever exacerbate this issue. ASPIRE evaluated an independent SABA-challenged environment program comprising physicians' training on Global Initiative for Asthma (GINA) recommendations and scientific evidence, patient education of proper asthma treatment and risks of SABA over reliance, and free-drug programs for budesonide-formoterol.
This observational cohort enrolled 180 adult asthma patients with SABA overuse from Philippines (60%), Taiwan (27%), and Thailand (13%) during 2022-2024. Two-step hypothesis tested: (1) ≥20% achieve SABA reduction to <3 canisters/year; if met, (2) healthcare resource utilization (HRU) costs decrease ≥10%, comparing 12-month pre-period versus 12-month post-period.
Participants (mean age 53.9±16.7 years, 67.8% female, asthma duration 12.5±11.7 years) had 38.1% partly controlled and 29.4% uncontrolled asthma at baseline; GINA severity: Step 3 (41.9%), Step 4 (27.5%), Step 5 (10.6%). Primary outcomes: 73.9% (133/180) reduced SABA to <3 canisters/year (95% confidence interval [CI]: 0.67-0.80, p<0.001). Mean HRU cost decreased 59.1% from $5,217 to $2,131 (difference $3,086; 95% CI: $2,211-$6,366, p<0.001). Secondary outcomes: SABA monotherapy decreased from 77.8% to 28.1%. Self-purchased SABA decreased from 46.1% to 2.8%.
This study demonstrated that implementation of a multi-component SABA-challenged environment program combining improved access, comprehensive GINA education on SABA risks, and patient engagement was associated with meaningful reductions in SABA overuse, improved adherence to international guideline recommendations, and substantial cost savings. These findings suggest that healthcare systems and policymakers across Asia should prioritize implementing similar interventions and strengthening chronic asthma care infrastructure to address preventable healthcare burden in the region.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
SABA overuse, healthcare resource utilization, real-world evidence
maximum 3 keywords and no abbreviations, separated by commas
This study was sponsored by AstraZeneca.
305